Ashley Brittain Landers practices in the firm’s Mass Tort department. She litigates cases on behalf of victims who allege injuries due to dangerous pharmaceutical drugs, defective medical devices, and toxic substances.
Ashley has been involved in a variety of mass tort cases involving pharmaceutical drugs, medical devices, and toxic torts. In the past, Ashley was involved in pharmaceutical and medical device national litigations involving Trasylol®, Levaquin®, DePuy ASR® hip devices, and transvaginal mesh products. Ashley also represented women in national contraceptive multidistrict litigations involving NuvaRing® and Yaz/Yasmin®. Ashley served on the Briefing, Expert, Science, and Discovery Committees for the NuvaRing® multidistrict litigation, and contributed to the successful Daubert and summary judgment briefing in preparation for the first trial in the United States District Court for the Eastern District of Missouri. Ashley also received a Missouri Lawyers Award in 2015 for her role in the NuvaRing® multidistrict litigation.
Ashley is currently representing clients in several national multidistrict litigation cases involving pharmaceutical drugs, including Xarelto®, Pradaxa®, and Actos®. Within the Xarelto® litigation, Ashley serves as the Co-Chair of the Clinical Trials Sub-Committee and Co-Chair of the Themes and Demonstratives Sub-Committee. Ashley also currently represents clients across southern Ohio and West Virginia in the national litigation involving alleged injuries due to exposure to the toxic chemical C-8. Ashley is also a regular speaker at national litigation conferences and seminars on multidistrict litigations and related topics.
Ashley graduated with honors from the University of Missouri School of Law, where she served as Director on the Board of Advocates, an editor on the Journal of Dispute Resolution, and was actively involved in the Domestic Violence Clinic. She was awarded National Order of the Barrister and Dean’s List Scholar. She also received the Fred L. Howard Prize for Excellence in the Advancement of Advocacy, which is awarded to a student who exhibits exceptional ability in trial advocacy.